Existence of JAK2 mutation 19 years prior to the development of overt polycythemia vera

Publisher： John Wiley & Sons Inc

E-ISSN： 1099-1069|36|1|355-356

ISSN： 0278-0232

Source： Hematological Oncology (Electronic), Vol.36, Iss.1, 2018-02, pp. : 355-356

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Emerging drugs for polycythemia vera

By Tibes Raoul   Mesa Ruben A  

Expert Opinion on Emerging Drugs, Vol. 18, Iss. 3, 2013-09 ,pp. : 393-404

Informa Healthcare

Access to resources Recommend Favorite

Polycythemia vera: can we do better?

By Shariff Farah   Harrison Claire  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 6, 2013-04 ,pp. : 687-689

Informa Healthcare

Access to resources Recommend Favorite

Imatinib: Emergence of JAK2V617F clone leading to polycythaemia vera, in an elderly patient?: case report

By  

Reactions Weekly, Vol. 1, Iss. 1315, 2010-01 ,pp. : 26-27

Adis International

Access to resources Recommend Favorite

Quantitative Assay for Janus Kinase 2 (JAK2) Mutation in Chinese Patients with Chronic Myeloproliferative Disorders

By Shen Y-M   Chao H-Y   Zhang R   Feng Y-F   Cen J-N   Yao L   Shen H-J   Zhu Z-L   Xue Y-Q  

The Journal of International Medical Research, Vol. 37, Iss. 1, 2009-01 ,pp. : 37-46

Field House Publishing

Access to resources Recommend Favorite

Comparison of JAK2V617F‐positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology

By  

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 269-275

John Wiley & Sons Inc

Access to resources Recommend Favorite